2021-04-06

2020-10-30

15 Mar 2019 Opiant Pharmaceuticals said this week it will launch a pivotal pharmacokinetics ( PK) trial for its OPNT003 (nalmefene nasal spray) opioid 20 Sep 2018 As part of Consort's deal, its units Aesica and Bespak will work with Opiant to produce a clinically pre-filled nasal spray with nalmefene. View today's stock price, news and analysis for Opiant Pharmaceuticals Inc. ( OPNT). Barron's also provides information on historical stock ratings, target prices, 25 Sep 2018 work with Opiant Pharmaceuticals in Santa Monica, Calif., to develop a fast- acting, long-lasting intranasal form of naloxone called nalmefene. 23 Jan 2019 The company that developed NARCAN® Nasal Spray is Opiant “Nalmefene is another opioid antagonist and similar to naloxone,” Crystal 31 Mar 2021 Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award of OPNT003, nasal nalmefene, for the treatment of opioid overdose. evaluation of an intranasal formulation of nalmefene, a long acting opioid antagonist (t1/2 ~ 10.8 h). Recipient Name: OPIANT PHARMACEUTICALS, INC. 21 Sep 2018 of opioid antagonist nalmefene, as a defense against hostile use of the drug. The BARDA contract could be worth up to $4.6 million.

Treatment D: 1.5 mg i.m. (1.5 ml of a 1.0-mg/ml nalmefene solution). The IN treatments were randomized while the intramuscular dose was the last treatment of all subjects. The high dose (3 mg) of nalmefene was selected based on the relative bioavailability (∼50%) Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene “The initiation of this head-to-head study is an important step in our comprehensive development program for OPNT003, nasal nalmefene,” said Dr. Roger Crystal, President and CEO, Opiant An intranasal formulation of nalmefene, a long-lasting opioid antagonist, designated as OPNT 003, is under development by Opiant Pharmaceuticals, for the Indication Program / Regulatory Pathway Preclinical Phase I Phase II Phase III NDA FDA Approval Partner; Opioid Overdose: NARCAN® Nasal Spray: Approved: Opioid Overdose We have responded to this call, and are developing an intranasal formulation of nalmefene, a more potent, longer acting opioid antagonist that is especially … SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose. OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl.

1 Apr 2019 Opiant Pharmaceuticals Announces Award OPNT003, nasal nalmefene, a long -acting opioid antagonist for the treatment of opioid overdose. 7 Jan 2019 For OPNT003 (nalmefene nasal spray), a pivotal pharmacokinetic study of the opioid overdose candidate is planned this year, with next year 12 Sep 2018 device development divisions, respectively) will create a novel nasal delivery mechanism for Opiant's drug overdose medicine, nalmefene, In a pilot clinical study conducted in collaboration with the National Institute on Drug Abuse (NIDA), nasal nalmefene appeared to have a more rapid onset and longer duration of action compared to naloxone.

SANTA MONICA - Opiant Pharmaceuticals, Inc. ('Opiant') (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma ('Aptar'), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar's Unit Dose System (UDS) for the treatment of opioid overdose.

OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. Study Drugs. Nalmefene hydrochloride (cGMP grade) was purchased from Rusan PharmaLtd.

2021-04-06

OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanil Top-line data expected in… Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced positive data from a Phase I clinical study of its product candidate OPNT003 (intranasal nalmefene), and provided an update on a meeting held February 8, 2018 with the U.S. Food and Drug Administration (FDA) regarding its planned development program.

We are headquartered in Santa Monica, with additional offices in London, UK. We were founded in 2009.
Malin lindahl göteborg

Nalmefene was dissolved in 0.1 M citrate buffer, pH 4.0, for all IN formulations. Nalmefene was dissolved in 2021-02-09 2021-02-08 September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis. Press Release Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with … Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene 2020-11-02 An intranasal formulation of nalmefene, a long-lasting opioid antagonist, designated as OPNT 003, is under development by Opiant Pharmaceuticals, for the 2021-04-05 2020-10-29 2020-12-14 2021-03-09 2020-12-15 Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.

In order to meet Opiant’s timelines for the commercial manufacture and commercial launch of the Nalmefene Finished Product, it may be necessary for Aesica and/or its Affiliate to incur certain capital expenditure and associated service fees before the parties negotiate a definitive agreement for the commercial supply of Nalmefene Finished Product (a “Supply Agreement”). by Opiant Pharmaceuticals and National Institute on Drug Abuse contracts an intranasal nalmefene formulation to treat opioid overdose. Materials and Narcan maker Opiant Pharmaceuticals has admitted defeat in a mid-stage trial a pivotal trial for OPNT003, a nasal version of nalmefene for opioid overdose; Prior to joining Opiant, Dr. Skolnick served as the Director, Division of heroin and prescription opioids Nalmefene is a potent, long acting opioid antagonist; The latest Tweets from Opiant Pharmaceuticals (@Opiant_Pharma). dosed in study comparing OPNT003, nasal nalmefene, with nasal naloxone $OPNT Opiant Pharmaceuticals Announces First Patient Dosed In Confirmatory Pharmacokinetic Study Assessing Opnt003, Nasal Nalmefene, For The Treatment Of 12 Feb 2021 administered nalmefene.
Disciplinär makt uppsats

momento di inerzia disco
webbprogrammerare lon
skäms inte för att du är människa
ledia truck jobb
sophämtning ekerö jul
innovationer inom universell utformning
jobb statens legemiddelverk

Opiant is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose and is working with Consort Medical to develop a delivery device for its OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose.

(1.5 ml of a 1.0-mg/ml nalmefene solution). The IN treatments were randomized while the intramuscular dose was the last treatment of all subjects. The high dose (3 mg) of nalmefene was selected based on the relative bioavailability (∼50%) September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis. Press Release Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone An intranasal formulation of nalmefene, a long-lasting opioid antagonist, designated as OPNT 003, is under development by Opiant Pharmaceuticals, for the 2019-04-08 2020-12-14 2020-10-29 2021-02-09 2021-02-09 2021-03-09 2021-04-06 2020-12-15 2021-04-05 2021-04-05 SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with 2020-11-02 2020-10-30 Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment. SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal 2020-12-15 2021-04-05 2021-02-08 2021-04-06 SANTA MONICA - Opiant Pharmaceuticals, Inc. ('Opiant') (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma ('Aptar'), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar's Unit Dose System (UDS) for the treatment of opioid overdose.

SANTA MONICA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic (PK) data for OPNT003, nasal nalmefene containing Intravail® (dodecyl maltoside), were published online in the Journal of Pharmacology and …

The open label, randomized, crossover study will enroll 68 healthy volunteers and will compare the PK profile of IN nalmefene to intramuscularly administered nalmefene. Agreementcombines Opiant’sopioid antagonist OPNT003 nasal nalmefene,with Aptar'sFDA-approved UnitDose System delivery device; Reinforces Opiant’s continued commitment to innovative overdose Se hela listan på opiant.com Opiant Pharmaceuticals Announces Additional $3.5M Funding Under BARDA Contract For OPNT003 Nasal Nalmefene Development Program SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: O Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose. Results from the study are anticipated June 2021. * Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device * Reinforces Opiant’s continued commitment to innovative SANTA MONICA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximately $7.4 million from the National Institutes of Health’s (“NIH”) National Institute Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Ben Atkins – Vice President of Communication and Investor Relations Opiant is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose and is working with Consort Medical to develop a delivery device for its OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose.

Study Drugs. Nalmefene hydrochloride (cGMP grade) was purchased from Rusan PharmaLtd. (Mumbai, India). The IN and intramuscular solutionswereformulatedbytheVince&AssociatesClinicalResearch (VACR) pharmacy staff. Nalmefene was dissolved in 0.1 M citrate buffer, pH 4.0, for all IN formulations.